Clinical trial results:
A Multicenter, Randomized, Double-Blinded, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Materian in Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Summary

EudraCT number	2021-000724-35
Trial protocol	DE IT ES
Global end of trial date	

Results information

Result version number	v1
This version publication date	01 November 2022
First version publication date	01 November 2022

Trial information

Trial identification

Sponsor protocol code	VIR-7831-5006

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04779879
WHO universal trial number (UTN)	-
Other trial identifiers	VIR-7831-5006: GSK216912

Notes:

Sponsors

Sponsor organisation name	Vir Biotechnology, Inc.
Sponsor organisation address	499 Illinois St , San Francisco , United States, 94158
Public contact	n/a, GlaxoSmithKline (Ireland) Limited, 1415 6545281, na.na@na.com
Scientific contact	n/a, GlaxoSmithKline (Ireland) Limited, 1415 6545281, na.na@na.com
Sponsor organisation name	Vir Biotechnology, Inc.
Sponsor organisation address	499 Illinois St , San Francisco , United States, 94158
Public contact	Study Inquiry, Vir Biotechnology, Inc., 415 6545281, clinicaltrials@vir.bio
Scientific contact	Study Inquiry, Vir Biotechnology, Inc., clinicaltrials@vir.bio

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	18 November 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 August 2021
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

Safety (Part A): To evaluate the safety and tolerability profile of intravenous (IV) VIR-7831 Generation (Gen2) and IV Gen1

Pharmacodynamics (Part B): To evaluate the virological response of VIR-7831 Gen2 administered IV and via intramuscular (IM) injection in the upper respiratory tract

Protection of trial subjects:

Study participants were closely monitored for the occurrence of infusion reactions. The study intervention was administered in a clinic/study unit where participants were monitored closely for adverse events in the post-infusion period. Subsequent visits for study activities and clinical monitoring were conducted via clinic or home nursing visits (except for Week 16 which was a follow-up by telephone).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 February 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 276
Country: Number of subjects enrolled	Canada: 28
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 3
Country: Number of subjects enrolled	Spain: 46
Worldwide total number of subjects	353
EEA total number of subjects	46

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	337
From 65 to 84 years	16
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Randomized, parallel group study conducted in non-hospitalized participants with mild to moderate Coronavirus Disease 2019 (COVID-19) who received Sotrovimab (VIR-7831) Generation1 (Gen 1) and Gen2. Results presented are based on the primary analysis (data up to Day 29). Additional results will be provided within 1 year after study completion.

Pre-assignment

Screening details:

Total of 354 participants (30 participants in Part A, 167 participants in Part B, 157 participants in Part C) were enrolled in the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part A- Sotrovimab Gen1: 500 mg IV

Arm description:

Participants received Sotrovimab (VIR-7831) Gen1 500 milligrams (mg) intravenous (IV) infusion on Day 1 in Part A.

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sotrovimab was administered as IV infusion

Arm title	Part A- Sotrovimab Gen2: 500 mg IV

Arm description:

Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part A.

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sotrovimab was administered as IV infusion

Arm title	Part B- Sotrovimab Gen2: 500 mg IV

Arm description:

Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part B.

Arm type	Experimental

Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sotrovimab was administered as IV infusion and IM injection

Arm title	Part B- Sotrovimab Gen2: 500 mg IM

Arm description:

Participants received Sotrovimab (VIR-7831) Gen2 500 mg intramuscular (IM) injection on Day 1 in Part B.

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Sotrovimab was administered as IM injection

Arm title	Part C- Sotrovimab Gen2: 500 mg IV

Arm description:

Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part C.

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sotrovimab was administered as IV infusion

Arm title	Part C- Sotrovimab Gen2: 250 mg IM

Arm description:

Participants received Sotrovimab (VIR-7831) Gen2 250 mg IM injection on Day 1 in Part C.

Arm type	Experimental
Investigational medicinal product name	Sotrovimab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Sotrovimab was administered as IM injection

Number of subjects in period 1	Part A- Sotrovimab Gen1: 500 mg IV	Part A- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IV
Started	8	22	84
Completed	0	0	0
Not completed	8	22	84
Consent withdrawn by subject	-	-	-
Death	-	-	-
Ongoing in the study	8	22	84

Number of subjects in period 1	Part B- Sotrovimab Gen2: 500 mg IM	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM
Started	82	79	78
Completed	0	0	0
Not completed	82	79	78
Consent withdrawn by subject	-	1	-
Death	-	-	1
Ongoing in the study	82	78	77

Baseline characteristics

Reporting groups	
Reporting group title	Part A- Sotrovimab Gen1: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen1 500 milligrams (mg) intravenous (IV) infusion on Day 1 in Part A.	
Reporting group title	Part A- Sotrovimab Gen2: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part A.	
Reporting group title	Part B- Sotrovimab Gen2: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part B.	
Reporting group title	Part B- Sotrovimab Gen2: 500 mg IM
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg intramuscular (IM) injection on Day 1 in Part B.	
Reporting group title	Part C- Sotrovimab Gen2: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part C.	
Reporting group title	Part C- Sotrovimab Gen2: 250 mg IM
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 250 mg IM injection on Day 1 in Part C.	

Reporting group values	Part A- Sotrovimab Gen1: 500 mg IV	Part A- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IV
Number of subjects	8	22	84
Age categorical			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
<=18 years	0	1	0
19-64 years	8	20	80
>=65 years	0	1	4
Gender categorical			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
Female	5	10	45
Male	3	12	39
Race/ Ethnicity, Customized			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
Black or African American	2	1	4
White - White/Caucasian/European Heritage	6	21	62
White - Arabic/North African Heritage	0	0	5
Asian - East Asian Heritage	0	0	2
Asian - South East Asian Heritage	0	0	11
Asian - Central/South Asian Heritage	0	0	0
American Indian Or Alaska Native	0	0	0

Mixed Asian Race	0	0	0

Reporting group values	Part B- Sotrovimab Gen2: 500 mg IM	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM
Number of subjects	82	79	78
Age categorical			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
<=18 years	1	0	0
19-64 years	76	77	74
>=65 years	5	2	4
Gender categorical			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
Female	42	39	42
Male	40	40	36
Race/ Ethnicity, Customized			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
Black or African American	1	7	9
White - White/Caucasian/European Heritage	64	66	63
White - Arabic/North African Heritage	0	6	5
Asian - East Asian Heritage	2	0	0
Asian - South East Asian Heritage	13	0	0
Asian - Central/South Asian Heritage	1	0	0
American Indian Or Alaska Native	0	0	1
Mixed Asian Race	1	0	0

Reporting group values	Total		
Number of subjects	353		
Age categorical			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
<=18 years	2		
19-64 years	335		
>=65 years	16		
Gender categorical			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
Female	183		
Male	170		
Race/ Ethnicity, Customized			
Safety Population consisted of all randomized participants who were exposed to study intervention.			
Units: Subjects			
Black or African American	24		
White - White/Caucasian/European Heritage	282		

White - Arabic/North African Heritage	16		
Asian - East Asian Heritage	4		
Asian - South East Asian Heritage	24		
Asian - Central/South Asian Heritage	1		
American Indian Or Alaska Native	1		
Mixed Asian Race	1		

End points

End points reporting groups

Reporting group title	Part A- Sotrovimab Gen1: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen1 500 milligrams (mg) intravenous (IV) infusion on Day 1 in Part A.	
Reporting group title	Part A- Sotrovimab Gen2: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part A.	
Reporting group title	Part B- Sotrovimab Gen2: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part B.	
Reporting group title	Part B- Sotrovimab Gen2: 500 mg IM
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg intramuscular (IM) injection on Day 1 in Part B.	
Reporting group title	Part C- Sotrovimab Gen2: 500 mg IV
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 500 mg IV infusion on Day 1 in Part C.	
Reporting group title	Part C- Sotrovimab Gen2: 250 mg IM
Reporting group description:	
Participants received Sotrovimab (VIR-7831) Gen2 250 mg IM injection on Day 1 in Part C.	

Primary: Part A: Number of Participants With all Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29

End point title	Part A: Number of Participants With all Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29[1][2]

End point description:

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, significant medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed before.

Safety Population consisted of all randomized participants who were exposed to study intervention.

End point type	Primary

End point timeframe:

Up to Day 29

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There are no statistical data to report.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part A-Sotrovimab Gen1: 500 mg IV	Part A-Sotrovimab Gen2: 500 mg IV		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8[3]	22[4]		
Units: Participants				
All AEs	0	3		
SAEs	0	0		

Notes:

[3] - Safety Population

[4] - Safety Population

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Participants With Adverse Events of Special Interest (AESI) Through Day 29

End point title	Part A: Number of Participants With Adverse Events of Special Interest (AESI) Through Day 29[5][6]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs were infusion site reactions; cardiac events of special interest and renal events of special interest.

End point type	Primary

End point timeframe:

Up to Day 29

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There are no statistical data to report.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part A-Sotrovimab Gen1: 500 mg IV	Part A-Sotrovimab Gen2: 500 mg IV		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	22		
Units: Participants				
Infusion site reactions	0	0		
Cardiac events of special interest	0	0		
Renal events of special interest	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Participants With Worst-case Post Baseline Abnormal

Electrocardiogram (ECG) Findings Through Day 29

End point title	Part A: Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings Through Day 29[7][8]

End point description:

Twelve-lead ECGs were recorded with the participant in a semi-supine position after being at rest for at least 10 minutes using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented.

End point type	Primary

End point timeframe:

Up to Day 29

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There are no statistical data to report.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part A-Sotrovimab Gen1: 500 mg IV	Part A-Sotrovimab Gen2: 500 mg IV		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	22		
Units: Participants				
Abnormal-Clinically significant	0	0		
Abnormal-Not Clinically significant	6	17		

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29

End point title	Part A: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29[9][10]

End point description:

AEs related to expected progression, signs, or symptoms of COVID-19, unless more severe than expected for the participant’s current clinical status and medical history, were reported as a Disease-Related Events (DRE).

End point type	Primary

End point timeframe:

Up to Day 29

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There are no statistical data to report.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part A-Sotrovimab Gen1: 500 mg IV	Part A-Sotrovimab Gen2: 500 mg IV		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	22		
Units: Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Mean Area Under the Curve (AUC) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Viral Load From Day 1 to Day 8 (AUCD1-8)

End point title	Part B: Mean Area Under the Curve (AUC) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Viral Load From Day 1 to Day 8 (AUCD1-8)[11]

End point description:

AUC of SARS-CoV-2 viral load was measured by Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) from Day 1 to Day 8 in nasopharyngeal (NP) swab samples. Analysis was performed using an Analysis of covariance (ANCOVA) model with covariates of treatment and Baseline logarithm (base 10) viral load.
Viral Pharmacodynamic Population consisted of all participants in the Safety Population who had a Baseline (Day 1) quantifiable viral load as assessed using qRT-PCR from NP swabs. Only those participants with data available at the specified time points without missing covariate information were analyzed.

End point type	Primary

End point timeframe:

Day 1 to Day 8

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	65		
Units: Day*log10 copies per (/) milliliter (mL)				
least squares mean (confidence interval 90%)	24.40 (23.53 to 25.31)	25.28 (24.38 to 26.21)		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Analysis was performed using an Analysis of covariance (ANCOVA) model with covariates of treatment and Baseline logarithm (base 10) viral load.

Comparison groups	Part B- Sotrovimab Gen2: 500 mg IV v Part B- Sotrovimab Gen2: 500 mg IM
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Ratio of geometric least squares mean
Point estimate	1.04
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.98
upper limit	1.09

Primary: Part C: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 8 (AUCD1-8)

End point title	Part C: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 8 (AUCD1-8)[12]

End point description:

AUC of SARS-CoV-2 viral load was measured by qRT-PCR from Day 1 to Day 8 in NP swab samples. Analysis was performed using an ANCOVA model with covariates of treatment, and Baseline logarithm (base10) viral load and randomization stratification factor (prior exposure to an authorized or approved SARS-CoV-2 vaccine).

End point type	Primary

End point timeframe:

Day 1 to Day 8

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	55	62		
Units: Day*log10 copies/mL				
least squares mean (confidence interval 90%)	26.20 (24.68 to 27.81)	26.72 (25.26 to 28.27)		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Analysis was performed using an ANCOVA model with covariates of treatment, and Baseline logarithm (base10) viral load and randomization stratification factor (prior exposure to an authorized or approved SARS-CoV-2 vaccine).

Comparison groups	Part C- Sotrovimab Gen2: 500 mg IV v Part C- Sotrovimab Gen2: 250 mg IM

Number of subjects included in analysis	117
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Ratio of geometric least squares mean
Point estimate	1.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.94
upper limit	1.11

Secondary: Part B: Number of Participants with AEs and SAEs Through Day 29

End point title	Part B: Number of Participants with AEs and SAEs Through Day 29[13]

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, significant medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed before. Adverse events include both Serious and Other Adverse Events.

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	82		
Units: Participants				
AEs	8	17		
SAEs	1	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Number of Participants With AESI Through Day 29

End point title	Part B: Number of Participants With AESI Through Day 29[14]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study intervention, whether or not considered related to the

study intervention. AESIs were injection-related reactions (IRR) including hypersensitivity reactions; injection site reactions (ISRs); cardiac events of special interest and renal events of special interest.

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	82		
Units: Participants				
IRR including hypersensitivity	0	1		
Injection site reactions	0	9		
Cardiac events of special interest	0	0		
Renal events of special interest	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Number of Participants With Worst-case Post Baseline Abnormal ECG Findings Through Day 29

End point title	Part B: Number of Participants With Worst-case Post Baseline Abnormal ECG Findings Through Day 29[15]

End point description:

Twelve-lead ECGs were recorded with the participant in a semi-supine position after being at rest for at least 10 minutes using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented.

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	82		
Units: Participants				
Abnormal-Clinically significant	1	1		
Abnormal-Not Clinically significant	43	39		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29

End point title	Part B: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29[16]

End point description:

AEs related to expected progression, signs, or symptoms of COVID-19, unless more severe than expected for the participant's current clinical status and medical history, were reported as a Disease-Related Events (DRE).

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	82		
Units: Participants	0	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Number of Participants With AEs and SAEs Through Day 29

End point title	Part C: Number of Participants With AEs and SAEs Through Day 29[17]

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant

disability/incapacity, is a congenital anomaly/birth defect, significant medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed before. Adverse events include both Serious and Other Adverse Events.

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV	Part C-Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79	78		
Units: Participants				
AEs	10	13		
SAEs	1	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Number of Participants With AESI Through Day 29

End point title	Part C: Number of Participants With AESI Through Day 29[18]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs were injection-related reactions (IRR) including hypersensitivity reactions; injection site reactions (ISRs); cardiac events of special interest and renal events of special interest.

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV	Part C-Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79	78		
Units: Participants				
IRR including hypersensitivity	0	0		
Injection site reactions	0	3		
Cardiac events of special interest	0	0		

Renal events of special interest	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Number of Participants With Worst-case Post Baseline Abnormal ECG Findings Through Day 29

End point title	Part C: Number of Participants With Worst-case Post Baseline Abnormal ECG Findings Through Day 29[19]

End point description:

Twelve-lead ECGs were recorded with the participant in a semi-supine position after being at rest for at least 10 minutes using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented.

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV	Part C-Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79	78		
Units: Participants				
Abnormal-Clinically significant	0	0		
Abnormal-Not Clinically significant	38	37		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29

End point title	Part C: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29[20]

End point description:

AEs related to expected progression, signs, or symptoms of COVID-19, unless more severe than expected for the participant’s current clinical status and medical history, were reported as a Disease-Related Events (DRE).

End point type	Secondary

End point timeframe:

Up to Day 29

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV	Part C-Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79	78		
Units: Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Change from Baseline in SARS-CoV-2 Saliva and Nasal Mid-Turbinate Viral Load

End point title	Part A: Change from Baseline in SARS-CoV-2 Saliva and Nasal Mid-Turbinate Viral Load[21]

End point description:

SARS-CoV-2 viral load was based on saliva and nasal mid-turbinate swab samples and was measured by qRT-PCR. Baseline log10 viral load was defined as the non-missing assessment taken at Day 1 excluding the NEG and <2.08 results. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

End point type	Secondary

End point timeframe:

Baseline, Days 2, 5, 8, 11, 15, 22 and 29

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part A-Sotrovimab Gen1: 500 mg IV	Part A-Sotrovimab Gen2: 500 mg IV		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	16		
Units: Log10 copies/mL				
arithmetic mean (standard deviation)				
Day 2: Saliva, n=4,11	-0.270 (± 0.4290)	-1.114 (± 0.9201)		
Day 5: Saliva, n=3,11	-0.780 (± 0.3404)	-2.620 (± 1.0199)		
Day 8: Saliva, n=3,11	-0.507 (± 0.5689)	-2.605 (± 1.4982)		
Day 11: Saliva, n=4,10	-1.043 (± 0.5940)	-2.881 (± 1.3963)		

Day 15: Saliva, n=4,11	-0.610 (± 1.3444)	-3.179 (± 1.2132)		
Day 22: Saliva, n=4,11	-1.043 (± 0.5940)	-3.284 (± 1.3210)		
Day 29: Saliva, n=4,11	-1.043 (± 0.5940)	-3.223 (± 1.3123)		
Day 2: Nasal mid-turbinate, n=5,16	-1.252 (± 0.9726)	-1.006 (± 1.2277)		
Day 5: Nasal mid-turbinate, n=4,16	-1.755 (± 1.1230)	-2.111 (± 1.2100)		
Day 8: Nasal mid-turbinate, n=4,16	-1.705 (± 0.7839)	-2.703 (± 1.7842)		
Day 11: Nasal mid-turbinate, n=5,16	-2.810 (± 1.3363)	-2.923 (± 1.5656)		
Day 15: Nasal mid-turbinate, n=5,16	-2.490 (± 1.3243)	-3.445 (± 1.7103)		
Day 22: Nasal mid-turbinate, n=5,16	-2.668 (± 1.2826)	-3.873 (± 1.9434)		
Day 29: Nasal mid-turbinate, n=5,16	-2.810 (± 1.3363)	-3.752 (± 1.8030)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Change from Baseline in Viral Load as Measured by qRT-PCR From Nasopharyngeal Swab Samples

End point title	Part B: Change from Baseline in Viral Load as Measured by qRT-PCR From Nasopharyngeal Swab Samples[22]

End point description:

Viral load was based on nasopharyngeal swab samples and was measured by qRT-PCR. Baseline log10 viral load was defined as the non-missing assessment taken at Day 1 excluding the "NEG" and "<2.08" results. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Viral Pharmacodynamic Population consisted of all participants in the Safety Population who had a Baseline (Day 1) quantifiable viral load as assessed using qRT-PCR from NP swabs. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline, Days 2, 3, 5, 8, 11, 15, 22 and 29

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	66	68		
Units: Log10 copies/mL				
arithmetic mean (standard deviation)				

Day 2: n=63,68	-1.146 (± 1.1558)	-0.611 (± 1.1518)		
Day 3: n=63,66	-1.438 (± 1.2033)	-1.306 (± 1.3132)		
Day 5: n=62,64	-2.578 (± 1.2480)	-2.352 (± 1.1655)		
Day 8: n=64,64	-3.069 (± 1.4553)	-3.254 (± 1.4193)		
Day 11: n=62,63	-3.522 (± 1.7148)	-3.574 (± 1.4907)		
Day 15: n=62,66	-3.705 (± 1.7443)	-3.733 (± 1.5525)		
Day 22: n=64,66	-3.831 (± 1.7994)	-3.778 (± 1.7476)		
Day 29: n=62,64	-3.933 (± 1.8253)	-3.857 (± 1.7455)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Change from Baseline in Viral Load as Measured by qRT-PCR From Nasopharyngeal Swab Samples

End point title	Part C: Change from Baseline in Viral Load as Measured by qRT-PCR From Nasopharyngeal Swab Samples[23]

End point description:

Viral load was based on nasopharyngeal swab samples and was measured by qRT-PCR. Baseline log10 viral load was defined as the non-missing assessment taken at Day 1 excluding the "NEG" and "<2.08" results. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Viral Pharmacodynamic Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline, Days 2, 3, 5, 8, 11, 15, 22 and 29

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV	Part C-Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	66		
Units: Log10 copies per milliliter				
log mean (standard deviation)				
Day 2: n=59,64	-0.429 (± 1.3835)	-0.519 (± 1.3273)		
Day 3: n=50,57	-0.905 (± 1.5202)	-1.123 (± 1.6172)		
Day 5: n=57,62	-2.076 (± 1.9648)	-1.967 (± 2.0218)		

Day 8: n=55,62	-3.122 (± 1.8234)	-3.180 (± 1.8324)		
Day 11: n=52,61	-3.617 (± 1.6870)	-3.738 (± 1.8168)		
Day 15: n=50,61	-3.719 (± 1.8248)	-3.836 (± 1.8148)		
Day 22: n=55,65	-3.693 (± 1.7647)	-3.956 (± 1.7492)		
Day 29: n=56,63	-3.761 (± 1.8167)	-3.963 (± 1.7189)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Percentage of Participants With Undetectable Viral Load

End point title	Part B: Percentage of Participants With Undetectable Viral

End point description:

Viral load was measured by qRT-PCR from nasopharyngeal swab samples. Viral load (log10 copies/mL) values recorded as negative were considered as undetectable viral load. Percentage of participants with undetectable viral load have been presented. Percentage values are rounded off.

Viral Pharmacodynamic Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Days 2, 3, 5, 8, 11, 15, 22 and 29

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV	Part B-Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	66	68		
Units: Percentage of participants				
number (not applicable)				
Day 2: n=63,68	10	4		
Day 3: n=63,66	11	9		
Day 5: n=62,64	23	27		
Day 8: n=64,64	34	38		
Day 11: n=62,63	58	51		
Day 15: n=62,66	61	73		
Day 22: n=64,66	73	74		
Day 29: n=62,64	81	84		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Percentage of Participants With Undetectable Viral Load

End point title	Part C: Percentage of Participants With Undetectable Viral

End point description:

Viral load was measured by qRT-PCR from nasopharyngeal swab samples. Viral load (log10 copies/mL) values recorded as negative were considered as undetectable viral load. Percentage of participants with undetectable viral load have been presented. Percentage values are rounded off.

Viral Pharmacodynamic Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Days 2, 3, 5, 8, 11, 15, 22 and 29

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV	Part C-Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	66		
Units: Percentage of participants				
number (not applicable)				
Day 2: n=59,64	10	5		
Day 3: n=50,57	10	14		
Day 5: n=57,62	28	16		
Day 8: n=55,62	42	39		
Day 11: n=52,61	63	72		
Day 15: n=50,61	82	80		
Day 22: n=55,65	80	88		
Day 29: n=56,63	88	86		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 5 (AUCD1-5)

End point title	Part B: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 5 (AUCD1-5)[26]

End point description:

AUC of SARS-CoV-2 viral load was measured by qRT-PCR from Day 1 to Day 5. Analysis was performed using an ANCOVA model with covariates of treatment and Baseline logarithm (base 10) viral load.

Viral Pharmacodynamic Population. Only those participants with data available at the specified time points without missing covariate information were analyzed.

End point type	Secondary

End point timeframe:

Day 1 to Day 5

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63[27]	65[28]		
Units: Day*log10 copies/mL				
least squares mean (confidence interval 90%)	16.4 (15.53 to 16.77)	16.97 (16.34 to 17.62)		

Notes:

[27] - Viral Pharmacodynamic Population.

[28] - Viral Pharmacodynamic Population.

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Analysis was performed using an ANCOVA model with covariates of treatment and Baseline logarithm (base 10) viral load.

Comparison groups	Part B- Sotrovimab Gen2: 500 mg IV v Part B- Sotrovimab Gen2: 500 mg IM
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Ratio of geometric least squares mean
Point estimate	1.05
Confidence interval	
level	90 %
sides	2-sided
lower limit	1
upper limit	1.11

Secondary: Part B: Mean Area Under the Curve (AUC) of SARS-CoV-2 Viral Load From Day 1 to Day 11 (AUCD1-11)

End point title	Part B: Mean Area Under the Curve (AUC) of SARS-CoV-2 Viral Load From Day 1 to Day 11 (AUCD1-11)[29]

End point description:

AUC of SARS-CoV-2 viral load was measured by qRT-PCR from Day 1 to Day 11. Analysis was performed using an ANCOVA model with covariates of treatment and Baseline logarithm (base 10) viral load.

End point type	Secondary

End point timeframe:

Day 1 to Day 11

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	65		
Units: Day*log10 copies/mL				
least squares mean (confidence interval 90%)	31.69 (30.60 to 32.82)	32.39 (31.28 to 33.53)		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Analysis was performed using an ANCOVA model with covariates of treatment and Baseline logarithm (base 10) viral load.

Comparison groups	Part B- Sotrovimab Gen2: 500 mg IV v Part B- Sotrovimab Gen2: 500 mg IM
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Ratio of geometric least squares mean
Point estimate	1.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.97
upper limit	1.07

Secondary: Part C: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 5 (AUCD1-5)

End point title	Part C: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 5 (AUCD1-5)[30]

End point description:

AUC of SARS-CoV-2 viral load was measured by qRT-PCR from Day 1 to Day 5. Analysis was performed using an ANCOVA model with covariates of treatment, Baseline logarithm (base 10) viral load and randomization stratification factor (prior exposure to an authorized or approved SARS-CoV-2 vaccine).

End point type	Secondary

End point timeframe:

Day 1 to Day 5

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	63		
Units: Day*log10 copies/mL				
least squares mean (confidence interval 90%)	17.42 (16.49 to 18.41)	17.56 (16.66 to 18.51)		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Analysis was performed using an ANCOVA model with covariates of treatment, Baseline logarithm (base 10) viral load and randomization stratification factor (prior exposure to an authorized or approved SARS-CoV-2 vaccine).

Comparison groups	Part C- Sotrovimab Gen2: 500 mg IV v Part C- Sotrovimab Gen2: 250 mg IM
Number of subjects included in analysis	120
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Ratio of geometric least squares mean
Point estimate	1.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.93
upper limit	1.09

Secondary: Part C: Mean Area Under the Curve (AUC) of SARS-CoV-2 Viral Load From Day 1 to Day 11 (AUCD1-11)

End point title	Part C: Mean Area Under the Curve (AUC) of SARS-CoV-2 Viral Load From Day 1 to Day 11 (AUCD1-11)[31]

End point description:

AUC of SARS-CoV-2 viral load was measured by qRT-PCR from Day 1 to Day 11. Analysis was performed using an ANCOVA model with covariates of treatment, Baseline logarithm (base 10) viral load and randomization stratification factor (prior exposure to an authorized or approved SARS-CoV-2 vaccine).

End point type	Secondary

End point timeframe:

Day 1 to Day 11

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	62		
Units: Day*log10 copies/mL				
least squares mean (confidence interval 90%)	33.02 (31.17 to 34.97)	33.63 (31.89 to 35.47)		

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Analysis was performed using an ANCOVA model with covariates of treatment, Baseline logarithm (base 10) viral load and randomization stratification factor (prior exposure to an authorized or approved SARS-CoV-2 vaccine).	
Comparison groups	Part C- Sotrovimab Gen2: 500 mg IV v Part C- Sotrovimab Gen2: 250 mg IM
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Ratio of geometric least squares mean
Point estimate	1.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.94
upper limit	1.1

Secondary: Part B: Percentage of Participants With a Persistently High Viral Load at Day 8

End point title	Part B: Percentage of Participants With a Persistently High Viral Load at Day 8[32]
End point description:	
Percentage of participants with a persistently high viral load were categorized as >=4.1 log10 copies/mL and <4.1 log10 copies/mL. Percentage of participants with a persistently high viral load at Day 8 was assessed via qRT-PCR in nasopharyngeal swab samples. Percentage of participants with a persistently high viral load at Day 8 has been presented. Percentage values are rounded off.	
End point type	Secondary
End point timeframe:	
Day 8	

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	64		
Units: Percentage of participants				
number (not applicable)				
>=4.1 log 10 copies/mL	17	11		
<4.1 log 10 copies/mL	83	89		

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Percentage of Participants With a Persistently High Viral Load at Day 8

End point title	Part C: Percentage of Participants With a Persistently High Viral Load at Day 8[33]

End point description:

Percentage of participants with a persistently high viral load were categorized as >=4.1 log10 copies/mL and <4.1 log10 copies/mL. Percentage of participants with a persistently high viral load at Day 8 was assessed via qRT-PCR in nasopharyngeal swab samples. Percentage of participants with a persistently high viral load at Day 8 has been presented. Percentage values are rounded off.

Viral Pharmacodynamic Population. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Day 8

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	55	62		
Units: Percentage of participants				
number (not applicable)				
>=4.1 log 10 copies/mL	15	13		
<4.1 log 10 copies/mL	85	87		

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Cmax of VIR-7831 after IV administration

End point title	Part B: Cmax of VIR-7831 after IV administration[34]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: Microgram per mL				
arithmetic mean (standard deviation)	140.2 (± 9.36)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Cmax of VIR-7831 after IM administration

End point title	Part B: Cmax of VIR-7831 after IM administration[35]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Microgram per mL				
arithmetic mean (standard deviation)	28.2 (± 15.98)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Cmax of VIR-7831 after IV administration

End point title	Part C: Cmax of VIR-7831 after IV administration[36]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: Microgram per mL				
arithmetic mean (standard deviation)	137.4 (± 32.97)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Cmax of VIR-7831 after IM administration

End point title	Part C: Cmax of VIR-7831 after IM administration[37]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab). Only those participants with data available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 250 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	7			
Units: Microgram per mL				
arithmetic mean (standard deviation)	11.4 (± 6.02)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Clast of VIR-7831 after IV administration

End point title	Part B: Clast of VIR-7831 after IV administration[38]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Microgram per mL				
arithmetic mean (standard deviation)	37.5 (± 11.01)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Clast of VIR-7831 after IM administration

End point title	Part B: Clast of VIR-7831 after IM administration[39]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Microgram per mL				
arithmetic mean (standard deviation)	24.6 (± 12.05)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Clast of VIR-7831 after IV administration

End point title	Part C: Clast of VIR-7831 after IV administration[40]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Microgram per mL				
arithmetic mean (standard deviation)	34.4 (± 13.03)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Clast of VIR-7831 after IM administration

End point title	Part C: Clast of VIR-7831 after IM administration[41]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 250 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Microgram per mL				
arithmetic mean (standard deviation)	11.1 (± 7.08)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Tmax of VIR-7831 after IV administration

End point title	Part B: Tmax of VIR-7831 after IV administration[42]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: Day				
median (full range (min-max))	0.028 (0.01 to 0.03)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Tmax of VIR-7831 after IM administration

End point title	Part B: Tmax of VIR-7831 after IM administration[43]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Day				
median (full range (min-max))	6.878 (3.68 to 28.94)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Tmax of VIR-7831 after IV administration

End point title	Part C: Tmax of VIR-7831 after IV administration[44]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C- Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: Day				
median (full range (min-max))	0.014 (0.01 to 0.02)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: Tmax of VIR-7831 after IM administration

End point title	Part C: Tmax of VIR-7831 after IM administration[45]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed. The time frame is beyond Day 29 as there were available pharmacokinetic (PK) data for some participants up to Day 57 (+/-4 days per protocol defined time point) that were included in the analysis.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C- Sotrovimab Gen2: 250 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	7			
Units: Day				
median (full range (min-max))	13.993 (6.93 to 33.89)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: tlast of VIR-7831 after IV administration

End point title	Part B: tlast of VIR-7831 after IV administration[46]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Day				
median (full range (min-max))	27.580 (6.70 to 28.68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: tlast of VIR-7831 after IM administration

End point title	Part B: tlast of VIR-7831 after IM administration[47]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

The upper value of the full range is outside of the time frame due to the protocol defined time point of Day 29+/-2 days.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	11[48]			
Units: Day				
median (full range (min-max))	27.820 (14.10 to 29.78)			

Notes:

[48] - Pharmacokinetic Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: tlast of VIR-7831 after IV administration

End point title	Part C: tlast of VIR-7831 after IV administration[49]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

The time frame is beyond Day 29 as there were available PK data for some participants up to Day 57 (+/-4 days per protocol defined time point) that were included in the analysis.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Day				
median (full range (min-max))	27.809 (25.91 to 53.05)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: tlast of VIR-7831 after IM administration

End point title	Part C: tlast of VIR-7831 after IM administration[50]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

The time frame is beyond Day 29 as there were available PK data for some participants up to Day 57 (+/-4 days per protocol defined time point) that were included in the analysis.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 250 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Day				
median (full range (min-max))	28.552 (25.93 to 52.03)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: AUCD1-29 of VIR-7831 after IV administration

End point title	Part B: AUCD1-29 of VIR-7831 after IV administration[51]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	1407.6 (± 285.53)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: AUCD1-29 of VIR-7831 after IM administration

End point title	Part B: AUCD1-29 of VIR-7831 after IM administration[52]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	671.3 (± 415.34)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: AUCD1-29 of VIR-7831 after IV administration

End point title	Part C: AUCD1-29 of VIR-7831 after IV administration[53]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

Only those participants with data available at the specified data points were analyzed.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	1510.3 (± 444.32)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: AUCD1-29 of VIR-7831 after IM administration

End point title	Part C: AUCD1-29 of VIR-7831 after IM administration[54]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

Only those participants with data available at the specified data points were analyzed.

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 250 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	380.8 (± 251.26)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: AUClast of VIR-7831 after IV administration

End point title	Part B: AUClast of VIR-7831 after IV administration[55]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	1307.7 (±			

398.12)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: AUClast of VIR-7831 after IM administration

End point title	Part B: AUClast of VIR-7831 after IM administration[56]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29 (+/-2 days)

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part B-Sotrovimab Gen2: 500 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	642.7 (± 373.53)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: AUClast of VIR-7831 after IV administration

End point title	Part C: AUClast of VIR-7831 after IV administration[57]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose, end of infusion; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 500 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	1563.8 (± 492.08)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part C: AUClast of VIR-7831 after IM administration

End point title	Part C: AUClast of VIR-7831 after IM administration[58]

End point description:

Blood samples were collected at indicated time points for pharmacokinetic analysis of VIR-7831 (Sotrovimab).

End point type	Secondary

End point timeframe:

Day 1: Pre-dose; Days 2, 3, 5, 8, 15, 29, 57 (+/-4 days)

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is only reporting on a subset of the arms that are contained in the Baseline period.

End point values	Part C-Sotrovimab Gen2: 250 mg IM			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Day*microgram/mL				
arithmetic mean (standard deviation)	380.6 (± 259.90)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-cause mortality, non-serious AEs and SAEs were collected up to Day 29 in Parts A, B and C

Adverse event reporting additional description:

Safety Population consisted of all randomized participants who were exposed to study intervention. The results presented are based on the primary analysis (data up to Day 29). Additional results will be provided within one year after study completion.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	24.1

Reporting groups

Reporting group title	Part A- Sotrovimab Gen1: 500 mg IV
Reporting group description: -	
Reporting group title	Part A- Sotrovimab Gen2: 500 mg IV
Reporting group description: -	
Reporting group title	Part B- Sotrovimab Gen2: 500 mg IV
Reporting group description: -	
Reporting group title	Part B- Sotrovimab Gen2: 500 mg IM
Reporting group description: -	
Reporting group title	Part C- Sotrovimab Gen2: 500 mg IV
Reporting group description: -	
Reporting group title	Part C- Sotrovimab Gen2: 250 mg IM

Reporting group description: -

Serious adverse events	Part A- Sotrovimab Gen1: 500 mg IV	Part A- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IV
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19 pneumonia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part B- Sotrovimab Gen2: 500 mg IM	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 82 (2.44%)	1 / 79 (1.27%)	3 / 78 (3.85%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19 pneumonia			
subjects affected / exposed	1 / 82 (1.22%)	1 / 79 (1.27%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Part A- Sotrovimab Gen1: 500 mg IV	Part A- Sotrovimab Gen2: 500 mg IV	Part B- Sotrovimab Gen2: 500 mg IV
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)	3 / 22 (13.64%)	7 / 84 (8.33%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Injection site pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Injection site nodule			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Injection site discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			

subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Investigations			
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	2
Restless legs syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	2 / 84 (2.38%)
occurrences (all)	0	0	2

Headache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 22 (4.55%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Iron deficiency anemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Diarrhea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Nausea			

subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Pain in jaw			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Blister infected			
subjects affected / exposed	0 / 8 (0.00%)	1 / 22 (4.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Sinusitis			

subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 22 (4.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Otitis media acute			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 8 (0.00%)	0 / 22 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part B- Sotrovimab Gen2: 500 mg IM	Part C- Sotrovimab Gen2: 500 mg IV	Part C- Sotrovimab Gen2: 250 mg IM
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 82 (20.73%)	9 / 79 (11.39%)	11 / 78 (14.10%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Hypertension			

subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Injection site pain			
subjects affected / exposed	9 / 82 (10.98%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	11	0	1
Injection site nodule			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	1	0	1
Injection site discomfort			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Peripheral swelling			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Investigations			
Brain natriuretic peptide increased			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0

Transaminases increased			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Restless legs syndrome			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Migraine			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anemia			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anemia			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
Vertigo			

subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	1	0	1
Motion sickness			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Diarrhea			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	2 / 82 (2.44%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	2	0	0
Myalgia			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	2	0	1
Neck pain			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Blister infected			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	1 / 82 (1.22%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	1	1	0
Sinusitis			
subjects affected / exposed	1 / 82 (1.22%)	1 / 79 (1.27%)	1 / 78 (1.28%)
occurrences (all)	1	1	1
Urinary tract infection			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Herpes zoster			

subjects affected / exposed	0 / 82 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences (all)	0	1	0
Otitis media acute			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 82 (1.22%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences (all)	1	0	0
Gout			
subjects affected / exposed	0 / 82 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	0	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 January 2021	Amendment 1: Protocol changes have been made to include nasal mid-turbinate swabs and resistance testing at the request of regulatory agencies.
03 March 2021	Amendment 2: Protocol changes have been made to add a second part (Part B) to this study to assess IM injection of VIR-7831 Gen2 material. The original treatment arms evaluating Gen2 and Gen1 material administered IV is designated Part A. Changes were made throughout the protocol to add information necessary for conducting Part B and to differentiate Part A and Part B procedures. Other changes include: removal of home nursing option for Part A study visits, an additional endpoint for the secondary safety objective for Part A, updates to endpoint wording for Part A, the addition of resistance analyses, updated background information based on new data, and clarifications throughout the protocol
08 April 2021	Amendment 3: Adding measurement of anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibody at Baseline and Day 29 to the study procedures to allow for exploratory analysis of immune response. Removing the requirement that at least 15 participants are enrolled in Part A before enrollment in Part B can begin so that Part B can begin without delay
18 May 2021	Amendment 4: Protocol changes have been made to add a third part (Part C) to this study to assess the safety, tolerability, immunogenicity, pharmacokinetics, and viral pharmacodynamics of a 250 milligram (mg) dose of VIR-7831 administered by IM injection. Changes were made throughout the protocol to add information necessary for conducting Part C procedures. Additionally, the post-dose monitoring time for Part B has been reduced to 1 hour after Joint Safety Review Team (JSRT) review on 13 May 2021. Other changes include: moving resistance analysis to an exploratory objective, providing updated data, clarification of inclusion and exclusion criteria, incorporated information from the Germany-specific protocol amendment, and other clarifications throughout the protocol.
29 October 2021	Amendment 5: Expanded the safety follow-up of all active participants through Week 36 (~5 half lives of sotrovimab).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported